Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2403-2408

  Stefanaki, K ^a   Tzardi, M ^a   Kouvidou, Ch ^b   Chaniotis, V ^a   Bolioti, M ^a   Vlychou, M ^a   Zois, M ^a   Kakolyris, S ^a   Delides, G ^a   Rontogianni, D ^c   Georgoulias, V ^a,d   Kanavaros, P ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c Venizelion Hospital of Heraklion   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Bax; Ki67; Lymphomas; mdm2; Mucosa; p21; p53; RD

Indexed keywords

KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; B CELL LYMPHOMA; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BCL-2-ASSOCIATED X PROTEIN; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 15444355382     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Levine A, Momand J, Finlay C: The p53 tumour suppressor gene. Nature 351: 453-456, 1992.
2. Nigro MJ, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989.
3. Gaidano G, Ballerini P, Gonz JZ, et al: P53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88: 5413-5417, 1997.
4. Villuendas R, Piris MA, Algara P, Sanchez-Beato M, Sanchez-Verde L, Martinez JC, et al: The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 82: 3151-3156, 1993.
5. Kocialkowski S, Pezzela F, Morrison H, Jones M, Laha S, Harris AL, et al: Mutations in the p53 gene are not limited to classic "hot spots" and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br J Haematol 89: 55-60, 1995.
6. Barak Y, Oren M: Enhanced binding of a 95 kd protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J 11: 2115-2121, 1992.
7. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm2 oncogene product fonns a complex with p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
8. Oliner JD, Pietenpol JA, Thiagalingam S, et al: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860, 1993.
9. Finlay CA: The mdm2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301-306, 1993.
10. Juven T, Barak Y, Zauberman A, George DL, Oren M: Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411-3416, 1993.
11. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm2 autoregulatory feedback loop. Genes and Dev 7: 1126-1132, 1993.
12. Chen CY, Oliner JD, Zhan Q, Fomace AJ Jr, Vogelstein B, Kastan MB: Interactions between p53 and mdm2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 91: 2684-2691, 1994.
13. El -Deiry WS, Tokino T, Velculesku VE, Levy DB, Parsons R, Trent JM, et al: Waf1, a potential mediator of p53 tumour suppression. Cell 75: 817-825, 1993.
14. Harper JW, Adami GY, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 75: 805-816, 1993.
15. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is universal inhibitor of cyclin kinase. Nature 366: 701-704, 1993.
16. Gu Y, Turk CW, Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20 k regulatory subunit. Nature 366: 707-710, 1993.
17. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.
18. Ladanyi M, Cha Ch, Lewis R, et al: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53: 16-18, 1993.
19. Reiferberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739, 1993.
20. Sheikh MS, Shao ZM, Hussain A, Fontana JA. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53: 3226-3228, 1993.
21. Bueso-Ramos CE, Yang Y, Leon E, et al: The human MDM2 oncogene is overexressed in leukemias. Blood 82: 2617-2623, 1993.
22. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, et al: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low grade lymphoma of B-cell origin. Blood 9: 3158-3165, 1994.
23. Chilosi M, Doglioni C, Menestrina F, Montagna L, Rigo A, Lestani M, et al: Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood 84: 42954300, 1994.
24. Saltdez CA, Yato T, Clark HM, et al: P53 mutation is associated with progression in follicular lymphoma. Blood 82: 1994-2004, 1993.
25. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143: 845-856, 1993.
26. Nakamura H, Said JW, Miller CW, Koeffler HP. Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas. Blood 82: 920-926, 1993.
27. Martinez JC, Mateo MS, Sanchez-Beato M, Villuendas R, Orrade JL, Algara P, et al: MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. J Pathol 177: 27-35, 1995.
28. Chilosi M, Doglioni C, Magalini A, et al: P21/waf-1 cyclin kinase inhibitor expression in non-Hodgkin's lymphomas: A potential marlcer of p53 tumour-suppressor gene function. Blood 88: 4012-4020, 1996.
29. Du M, Peng H, Singh N, Isaacson P.G, Pan L: The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 86: 4587-4593, 1995.
30. Peng H, Chen G, Du M, Singh N, Isaacson PG, Pan L: Replication error phenotype and p53 gene mutation in lymphomas of mucosa-associated lymphoid tissue. Am J Pathol 148: 643-648, 1996.
31. Du M, Singh N, Husseuin A, Isaacson P.G, Pan L: Positive correlation between apoptosis and proliferative indices in gastrointestinal lymphomas of mucosa-associated lymphoid tissue (MALT). J Pathol 178: 379-384, 1996.
32. Karp J, Broder S: Molecular foundations of cancer: new targets for intervention. Nature Medicine 4: 309-320, 1995.
33. Mateo MS, Sanchez-Beato M, Martinez JC, Orfao A, Orradre ZL, Piris MA. P53, Rb and bcl2 expression during the cell cycle: a study in phytohaemagglutinin stimulated lymphocytes and microwave irradiated lymphoid tissue sections. J Clin Pathol 48: 151-159, 1995.
34. Harbour JW, Lai S-L, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 247: 353-355, 1988.
35. Yokota J, Akiyama T, Fung Y-K, Benedict WF, Namda Y, Hanaska M, et al: Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3: 471-475, 1988.
36. T' ang A, Varley JM, Chakaraborty S, Murphee AL, Fung Y-KT: Structural rearrangements of the retinoblastoma gene in human breast carcinoma. Science 242: 263-266, 1988.
37. Lee EY-HP, To H, Shew J-Y, Brookstein R, Scully P, Lee W-H: Inactivation of the retinoblastoma suspeptibility gene in human breast cancers. Science 241: 218-221, 1988;.
38. Horowitz JM, Yandell DW, Park SH, Canning S, Whyte P, Buchkovich K, et al: Point mutational inactivation of the retinoblastoma antioncogene. Science 243: 937-940, 1989.
39. Brookstein R, Shew JY, Chen PL, Scully P, Lee WH: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated Rb gene; Science 247: 712-715, 1990.
40. Martinez JC, Piris MA, Sanchez-Beato M, Villuedas R, Orradre JL, Algara P, et al: Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction. J Pathol 169: 405-421, 1993.
41. Ashton-Key M, Biddolph SC, Stein H, Gatter KC, Mason DY. Heterogeneity of bcl2 expression in MALT lymphoma. Histopathology 26: 75-78, 1995.
42. VilluendasR, Piris MA, Orradre JL, Mollejo M, Rodriguez R, Morente M. Different bcl2 protein expression in high-grade B-cell lymphomas derived from lymph node or musosa-associated lymphoid tissue. Am J Pathol 139: 989-993, 199.
43. Navratil E, Gaulard P, Kanavaros P, et al: Expression of the bcl2 protein in B cell lymphomas arising from mucosa associated lymphoid tissue. J Clin Pathol 48: 18-21, 1995.
44. White E. Life, death, and the pursuit of apoptosis. Genes and Development 10: 1-15, 1996.
45. Reed JC. Bcl2 and the regulation of programmed cell death. J Cell Biology 124: 1-6, 199.
46. Cordell JL, Falini B, Erber WN, et al: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APMP Complexes). J Histochem Cytochem 32: 219-222, 198.
47. Miller PT, Grogan TM, Dahlberg S, et al: Prognostic significance of the Ki67 associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective southwest oncology group trial. Blood 83: 1460-1466, 1994.
48. Pezzella F, Morrison H, Jones M, Lane D, Harris AL, Mason DY. Immunohistochemical detection of p53 and bcl2 proteins in non-Hodgkin's lymphoma. Histopathology 22: 39-44, 199.
49. Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Post thymic T-cell lymphomas frequently overexpress p53 protein but infrequently exhibit gene mutations. Am J Pathol 144: 573-584, 199.
50. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, et al: P53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 166: 235-241, 1992.
51. Villuendas R, Pezzella F, Gatter K, et al: P21/waf1/cip1 and mdm2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, mdm2-, p21-immunophenotype associated with missense p53 mutations. J Pathol 181: 51-61, 1997.
52. M.Tzardi, Ch. Kouvidou, I. Panayiotides, et al: P53 protein expression in non-Hodgkin's lymphomas (NHL). Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1. J Clin Pathol Mol Pathol 49: M278-M282, 199.
53. Schott T, Reimer S, Jahns A, Ohlenbusch A, Ruschenburg I, Nagel H, et al: Point mutations and nucleotide insertions in the mdm2 zinc finger structure of human tumours. J Pathol 182: 54-61, 1997.
54. Landers JE, Haines DS, Straus JF, George DL: Enhanced translation: a novel model of mdm2 oncogene overexpression identified in human tumour cells. Oncogene 9: 2745-2751, 199.
55. Steinman RA, Huffman B, Iro A, Guillouf C, Liebermann DA, Houseini ME. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 9: 3389-3396, 1994.
56. Parker SB, Eichele G, Zhang P, Rawls A, Sands A, Bradley A, et al: P53 independent expression of p21 in muscle and other terminally differentiating cells. Science 267: 1024-1027, 1995.
57. Schlaifer D, KraJewski S, Galoin S, Rigal-Huguet F, Laurent G, Massip P, et al: Immunodetection of apoptosis-regulating proteins in Iymphomas from patients with and without human immunodeficiency virus infection. Am J Pathol 149: 177-185, 1996.